Page 1, 2, 3
Financial Disclosure
The company that produces ORËÁ, the chelating agent, was a financial contributor to the first study, but was not a financial contributor in any way to the second pilot study or the third study, which consisted of vegetable assays. Michael and I did this on our own time and our own money, to buy the equipment and to gear up to obtain and prepare the samples for the labs. We paid thousands of dollars for heavy metal assays on vegetable samples. The company that produces ORËÁ was not involved in the third study in any way, so there has been no conflict of interest.
 Michael Rosenbaum, MD
Dr. Rosenbaum holds a medical degree from Albert Einstein College of Medicine in New York, and a master's degree in biochemistry and metabolic medicine from Hebrew University in Jerusalem, with residence in psychiatry at UCSF and certification in medical acupuncture. His practice, located in the San Francisco Bay Area, emphasizes clinical nutrition, environmental medicine, allergy and immunology, antiaging medicine, and the treatment of chronic health conditions such as Lyme disease. Within integrative medicine, he has served as President and Vice President of the Orthomolecular Medical Society (OMS); editor of the Society's journal; Director and Vice President of the Orthomolecular Health Medicine Organization (OHM); and President and Board member for The Healthy Foundation. Additionally, Dr. Rosenbaum is the author of two successful books, SuperSupplements, and Solving the Puzzle of Chronic Fatigue Syndrome.
Preventive Medical Center of Marin
4340 Redwood Highway, Suite A-22
San Rafael, California 94903
415-927-9450
info@DrMichaelRosenbaum.com
www.DrMichaelRosenbaum.com
 E. Hubbard
Hubbard's academic background includes a Bachelor of Science in genetics/biochemistry from Oregon State University and two years of work toward a PhD in molecular biology and developmental genetics at the University of Minnesota. He has more than three decades of hands-on scientific experience, including research manager of multi-million dollar programs with major corporations such as Eli Lilly and Mitsubishi. He was co-founder and VP of research at Sungene Technologies Corp., and CEO of BioSource Technologies Corp. Within the field of organics, Hubbard has been consultant to a number of food companies and was founder and manager of PureHarvest Corp, a company that developed patented technology for growing crops such as rice without the use of herbicides and pesticides. Within integrative healthcare, he has conducted more than 10 years of research in the field of human aging, and he has served as a health coach to several thousand people.
ErnieHubbard@yahoo.com
415-215-8933
www.TheSageCenter.org
Resources
Life Health Science LLC
1375 E. Ninth St., Ste. 2800
Cleveland, Ohio 44114
216-706-6093
www.lhscience.com
 Editorial: Nancy Faass, MSW, MPH
Working collaboratively with clients, Ms. Faass has been active in the development, research, writing, and editing of more than 45 books on functional and integrative medicine by publishers that include Elsevier, Harper, McGraw-Hill, and a dozen other imprints. Director of Writers' Group Inc. for the past 20 years, she also develops articles, white papers, lab manuals, blogs, and Web content. To obtain a 20-minute phone consult at no charge, email info@HealthWritersGroup.com, or call 415-922-6234.
References
1. Li JM, Wang W, Lei S, Zhao LL, Zhou D, Xiong H. Misdiagnosis and long-term outcome of 13 patients with acute thallium poisoning in China. Clin Toxicol (Phila). 2014;52(3):181-186.
2. McMillan TM, Jacobson RR, Gross M. Neuropsychology of thallium poisoning. J Neurol Neurosurg Psychiatry. 1997;63(2):247-250.
3. Al Hammouri F, Darwazeh G, Said A, Ghosh RA. Acute thallium poisoning: series of ten cases. J Med Toxicol. Dec 2011;7(4):306-311.
4. Liu CH, Lin KJ, Wang HM, Kuo HC, Chuang WL, Weng YH, et al. Brain fluorodeoxyglucose positron emission tomography (¹8FDG PET) in patients with acute thallium intoxication. Clin Toxicol (Phila). 2013;51(3):167-173.
5. Cvjetko P, Cvjetko I, Pavlica M. Thallium toxicity in humans. Arh Hig Rada Toksikol. Mar 2010;61(1):111-119.
6. Peter A, Viraraghavan T. Thallium: a review of public health and environmental concerns. Environment International. 2005;31(4):493–501.
7. Moyar B. Chemical Analysis of ORËÁ™. Personal communication 10/27/15.
8. Tobin DJ. Hair in Toxicology: An Important Bio-monitor. Cambridge, UK: RSC Publishing. 2005:147.
9. Miller MA, Patel MM, Coon T. Prussian blue for treatment of thallium overdose in the US. Hosp Pharm. 2005;40:796-797.
10. Hoffman RS. Thallium toxicity and the role of Prussian blue in therapy. Toxicol Rev. 2003;22(1):29-40.
11. Yang Y, Brownell C, Sadrieh N, et al. Quantitative measurement of cyanide released from Prussian Blue.Clin Toxicol (Phila). 2007;45(7):776-781.
12. Pavilickova J, Abiral J, Smatanova M, et al. Uptake of thallium from artificially contaminated soils by kale (Brassica oleracea L. var. acephala). Plant Soil Environ. 2006;52(12):544-549.
13. Cvjetko P, Cvjetko I, Pavlica M. Thallium toxicity in humans. Arh Hig Rada Toksikol. Mar 2010;61(1):111-119.
14. Hubbard E. Sage Center Technical Publication 7.3 – 09-11-15. Mill Valley, CA: The Sage Center. 2015:1–45.
Page 1, 2, 3 |
